Lung

pp 1–1 | Cite as

Correction to: Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH

  • Henning Gall
  • Jean-Luc Vachiéry
  • Nobuhiro Tanabe
  • Michael Halank
  • Mauricio Orozco-Levi
  • Lisa Mielniczuk
  • MiKyung Chang
  • Kai Vogtländer
  • Ekkehard Grünig
Author Correction

Correction to: Lung  https://doi.org/10.1007/s00408-018-0100-3

The original version of this article unfortunately contained a mistake. In the “Results” section, the percentage of patients with inoperable or persistent/recurrent CTEPH included in the study was reported as 85%. This has been corrected to 68% with this erratum.

Copyright information

© The Author(s) 2018

Authors and Affiliations

  • Henning Gall
    • 1
  • Jean-Luc Vachiéry
    • 2
  • Nobuhiro Tanabe
    • 3
  • Michael Halank
    • 4
  • Mauricio Orozco-Levi
    • 5
  • Lisa Mielniczuk
    • 6
  • MiKyung Chang
    • 7
  • Kai Vogtländer
    • 8
  • Ekkehard Grünig
    • 9
  1. 1.Department of Internal MedicineJustus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL)GiessenGermany
  2. 2.Département de CardiologieCliniques Universitaires de Bruxelles, Hôpital ErasmeBrusselsBelgium
  3. 3.Department of Respirology and Department of Advanced Medicine in Pulmonary Hypertension, Graduate School of MedicineChiba UniversityChibaJapan
  4. 4.Medical Clinic 1/PneumologyUniversity Hospital Carl Gustav CarusDresdenGermany
  5. 5.Hospital Internacional de ColombiaFundación Cardiovascular de ColombiaSantanderColombia
  6. 6.University of Ottawa Heart InstituteOttawaCanada
  7. 7.Bayer AGBerlinGermany
  8. 8.Bayer AGWuppertalGermany
  9. 9.Center for Pulmonary HypertensionThorax Clinic at the University HospitalHeidelbergGermany

Personalised recommendations